SBH
TBPH icon

Segall Bryant & Hamill’s Theravance Biopharma TBPH Stock Holding History

Segall Bryant & Hamill’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$953K Buy
+56,052
New +$928K 0.01% 547

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Segall Bryant & Hamill's TBPH Position: Q2 2026 in Review

Segall Bryant & Hamill opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 56,052 shares worth $953K. The stake represents 0.01% of the portfolio and ranks #547 among its holdings.

179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Segall Bryant & Hamill held 56,052 shares of Theravance Biopharma worth $953K as of Q2 2026.
  • Theravance Biopharma was a new Segall Bryant & Hamill position in Q2 2026.
  • Theravance Biopharma made up 0.01% of Segall Bryant & Hamill's portfolio in Q2 2026, its #547 holding.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.